에 대한 최신 뉴스 Sierra Madre Gold (OTC:SMDRF) 주식

Sierra Madre Gold And Silver Ltd is engaged in the business of mineral exploration and development in Canada and Mexico. The company's projects include the La Guitarra project, the Tepic project, and the La Tigra project.

News

Small Cap Analysis

Commodities

Trading Ideas

NSUPF

ONGRF

SMDRF

VAULT INTELLIGENCE LTD by VAULT INTELLIGENCE LTD.

VLTLF

2025년까지 원자재의 긍정적인 추세가 계속될 것으로 보인다. 여러 지역에서 갈등과 불안정성이 심화됨에 따라, 안전한 관할권에 집중하는 주니어 원자재 상품 기업 목록을 살펴본다.

2025년 주목할 만한 원자재 상품주 4종목

SIERRA MADRE GOLD SILVER by Sierra Madre Gold and Silver Ltd.

Sierra Madre Gold And Silver Ltd

Wedbush analyst Seth Basham maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Neutral and raises the price target from $1200 to $1350.

Price Target

Analyst Ratings

ORLY

Wedbush Maintains Neutral on O'Reilly Automotive, Raises Price Target to $1350

On Wednesday, Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) authorized to pursue a plan to separate BD&#8217;s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43511126/bd-announces-intent-to-separate-biosciences-and-diagnostic-solutions-business-to-enhance-focus-dri" rel="noreferrer noopener">and capital allocation</a>.
Following the separation, New BD will be a pure-play medical technology company. It expects to drive concentrated investments in high-impact R&amp;D and disciplined capital allocation, including growth-accretive M&amp;A.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit</a>
Medical Essentials includes BD&#8217;s Medication Delivery Solutions and Specimen Management businesses, which manufacture products such as IV catheters, PICCS, flush and other essential vascular access and management solutions, blood collection solutions, syringes, and advanced needle technologies.
Connected Care includes BD&#8217;s Medication Management Solutions and Advanced Patient Monitoring businesses with smart devices that use automation, artificial intelligence, and analytics.
BioPharma Systems provides biologic drug delivery, development, and manufacturing of drug delivery devices for the pharmaceutical industry.
Interventional, which includes BD&#8217;s Urology &amp; Critical Care, Peripheral Intervention, and Surgery businesses, caters to conditions such as urinary incontinence, peripheral vascular disease, cancer, and hernias.
After the separation, the New BD is expected to have fiscal 2024 revenue of approximately&nbsp;$17.8 billion. Biosciences and Diagnostic Solutions is expected to have approximately&nbsp;$3.4 billion&nbsp;in fiscal 2024 revenue.
The company expects to announce more specifics on the separation plans by the end of fiscal 2025 and intends to target completion of the transaction in fiscal 2026.
In April 2022, Becton Dickinson spun off&nbsp;Embecta Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NYSE">EMBC</a>), a diabetes device maker, <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">into a standalone entity</a>.
In November, the company announced that it had decided to discontinue its insulin patch pump program and would&nbsp;<a target="_blank" href="https://www.benzinga.com/24/11/42197315/becton-dickinson-spinoff-embecta-stops-insulin-patch-pump-program-plans-restructuring-stock-jumps" rel="noreferrer noopener">initiate a restructuring plan</a>.
In July, Embecta, a manufacturer of disposable&nbsp;insulin pen needles&nbsp;and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/07/39916116/insulin-device-maker-embecta-weighs-sale-after-70-share-decline-following-becton-dickinson-spin-off" rel="noreferrer noopener">giant&nbsp;Becton, Dickinson</a>.
Concurrently, BD reported first-quarter 2025 adjusted EPS of $3.43 beating the consensus of $2.98. The company&#8217;s sales increased 9.8% year-over-year to $5.17 billion, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $5.1 billion</a>.
Guidance: BD updated its fiscal year 2025 revenue guidance from $21.9 billion-$22.1 billion to $21.7 billion-$21.9 billion compared to the consensus of $21.93 billion.
The company expects adjusted EPS of $14.30-$14.60, up from $14.25-$14.60 compared to the consensus of $14.40.
Price Action: BDX stock is down 3.88% at $235.56 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43527607/conocophillips-beats-q4-revenue-and-eps-estimates-sets-10b-return-of-capital-target" target="_blank" rel="noreferrer noopener">ConocoPhillips Beats Q4 Revenue And EPS Estimates, Sets $10B Return of Capital Target</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

General

EMBC

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business

Evercore ISI Group analyst Elizabeth Anderson maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and raises the price target from $240 to $260.

ALGN

Evercore ISI Group Maintains Outperform on Align Tech, Raises Price Target to $260

Wells Fargo analyst Joe O'Dea maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Overweight and raises the price target from $92 to $98.

Wells Fargo Maintains Overweight on Johnson Controls Intl, Raises Price Target to $98

WIIM

NVST

Envista Holdings shares are trading higher after the company reported better-than-expected Q4 financial results. Also, Wells Fargo and Morgan Stanley raised their respective price targets on the stock.

Wells Fargo analyst Joseph O'Dea maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Underweight and lowers the price target from $250 to $245.

Wells Fargo Maintains Underweight on Illinois Tool Works, Lowers Price Target to $245

Darling Ingredients shares are trading higher after the company reported better-than-expected Q4 EPS results.

Wedbush analyst Seth Basham reiterates Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Neutral and maintains $250 price target.

Reiteration

CVNA

Wedbush Reiterates Neutral on Carvana, Maintains $250 Price Target

CENT

Central Garden shares are trading higher after the company reported better-than-expected Q1 financial results.

Wells Fargo analyst Joseph O'Dea maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Overweight and raises the price target from $140 to $142.

Wells Fargo Maintains Overweight on Emerson Electric, Raises Price Target to $142

Wells Fargo analyst Colin Langan maintains Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) with a Underweight and lowers the price target from $9 to $8.

Wells Fargo Maintains Underweight on Ford Motor, Lowers Price Target to $8

Haemonetics shares are trading lower after the company reported Q3 financial results and missed its revenue estimate.

Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Equal-Weight and lowers the price target from $74 to $70.

CNMD

Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $70

Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Outperform and raises the price target from $34 to $36.

KURA

Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $36

Semiconductor equipment and material supplier Entegris&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) reported its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43522215/entegris-reports-results-for-fourth-quarter-of-2024" rel="noreferrer noopener">fiscal fourth-quarter 2024</a> earnings Thursday before the market opened.
What To Know: The company reported adjusted EPS of 84 cents, topping <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of 78 cents</a>. Entegris reported sales of $849.84 million, marking a 5% growth year-over-year and quashing the analyst consensus estimate of $823.12 million.
Segments: Materials Solutions revenue declined 1.1% to $361.08 million. Advanced Purity Solutions revenue grew by 9.2% to $491.19 million.
However, the company&#8217;s adjusted net sales, excluding the impact of divestitures, increased by 11% Y/Y.
Materials Solutions segment profit grew 45% to $771.22 million. Purity Solutions segment profit increased 14.4% to $134.97 million.
Entegris also reported other key financial indicators, including an adjusted EBITDA margin of 29.2% (versus 26.0% Y/Y), an adjusted operating margin of 23.5% (versus 20.7% Y/Y), and an adjusted gross margin of 45.6% (versus 42.4% Y/Y).
CEO Bertrand Loy noted that Entegris continued to outperform the market, with EBITDA growth twice its sales growth rate.
Loy flagged limited visibility outside of advanced logic and AI-driven applications as it enters 2025. The company will continue to fund critical investments that improve its long-term competitiveness and position it for the industry upturn. Loy found the company well-positioned for the upcoming technology node transitions, likely generating incremental content per wafer opportunities.
Outlook: The company issued guidance for the fiscal first quarter of 2025. Entegris anticipates sales between $775 million-$805 million versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimates of $796.26 million</a>. Furthermore, the company expects adjusted EPS from 64 cents to 71 cents below analyst estimates of 74 cents.
Entegris stock lost over 12% in the last 12 months as multiple Wall Street firms <a target="_blank" href="https://www.benzinga.com/quote/ENTG/analyst-ratings" rel="noreferrer noopener">slashed their price targets</a> after a dismal <a target="_blank" href="https://www.benzinga.com/news/24/11/41717366/whats-going-on-with-entegris-shares-monday" rel="noreferrer noopener">third-quarter print</a>. Loy told customers with significant exposure to AI applications performed well, but the rest of the industry continues to be challenged.
Price Action: ENTG stock is up 5.38% at $109.49 at the last check in Thursday.
Read next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43528027/hersheys-stock-pops-as-q4-earnings-beat-expectationsbut-cocoa-prices-loom-over-2025-outlook" target="_blank" rel="noreferrer noopener">Hershey&#8217;s Stock Pops As Q4 Earnings Beat Expectations—But Cocoa Prices Loom Over 2025 Outlook</a></li>
</ul>
Photo via Shutterstock

ENTG

Entegris Q4 Earnings: Revenue And Profit Beat, Warns of 2025 Uncertainty Beyond AI Growth

ASTS

AST SpaceMobile shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $30.

Wells Fargo analyst Vik Chopra maintains Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) with a Equal-Weight and raises the price target from $20 to $21.

Wells Fargo Maintains Equal-Weight on Envista Holdings, Raises Price Target to $21

IDCC

InterDigital shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 adjusted EPS guidance above estimates. The company also announced an increase in its quarterly dividend from $0.45 per share to $0.60.

Biotech

Lilly Exec Says U.S. Prescriptions Of Alzheimer's Drug Kisunla Steadily Increasing Since Launch

Wells Fargo analyst Michael Brown maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Equal-Weight and raises the price target from $77 to $83.

Wells Fargo Maintains Equal-Weight on Moelis, Raises Price Target to $83

Press Releases

Sierra Madre Provides Update on La Guitarra Progress

Sierra Madre Announces Closing ff $1 Million Private Placement

TSXV:SM

Sierra Madre Gold

2025년까지 원자재의 긍정적인 추세가 계속될 것으로 보인다. 여러 지역에서 갈등과 불안정성이 심화됨에 따라, 안전한 관할권에 집중하는 <a href="https://www.benzinga.com/markets/commodities" target="_blank" rel="noreferrer noopener">주니어 원자재 상품 기업</a> 목록을 살펴본다.
<h2>볼트 리튬</h2>
볼트 리튬(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/VLTLF#OTCQB">VLTLF</a>)는 <a href="https://www.benzinga.com/markets/commodities/24/06/39480795/exclusive-volt-lithium-ceo-touts-6b-cash-flow-opportunity" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">유전 염수에서 리튬 추출</a>을 위한 기술 발전에 주력하는 캐나다의 주니어 자원 회사이다. 이 회사는 독점적인 직접 <a href="https://www.benzinga.com/markets/commodities/24/06/39480795/exclusive-volt-lithium-ceo-touts-6b-cash-flow-opportunity" target="_blank" rel="noreferrer noopener">리튬 추출 기술</a>을 통해 총 생산 비용을 톤당 2,900달러 미만으로 달성할 수 있으므로 염수 기반 리튬의 최초 상업적 생산자가 되는 것을 목표로 하고 있다. 리튬 가격은 2022년 최고치인 8만 달러에서 하락한 후에도 톤당 1만 달러 선을 맴돌고 있다.
경험이 풍부한 기업가인 알렉스 와일리(Alex Wylie)의 리더십 아래, 이 회사는 텍사스 퍼미안 분지에 테스트 시설을 설립했다. 다음 이정표는 이 회사가 하루에 10,000배럴의 유전 염수를 처리할 수 있는 차세대 현장 장치를 시운전할 계획인 다음 몇 주에 걸쳐 예정되어 있다. 주가는 연초 대비 11.61% 상승했다.
<h2>노던 슈피리어</h2>
노던 슈피리어(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NSUPF#OTCQB">NSUPF</a>)는 퀘벡과 온타리오에 프로젝트를 둔 주니어 금광 회사이다. 이 회사는 치부가마우(Chibougamau) 광산 지구를 개발하는 데 주력하고 있으며, 여기에서 <a href="https://www.benzinga.com/markets/commodities/24/08/40135946/exclusive-northern-superior-ceo-simon-marcotte-explains-companys-strategic-expansion-future-p" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">300만 온스 이상</a>의 금 매장량을 보유한 4개 사이트를 소유하고 있다. 이 자원들은 물리적으로 가까이 위치해 있어 단일 운영 설계를 지원하고 단일 제련소에 공급할 수 있다.
CEO 사이먼 마코트(Simon Marcotte)는 벤징가와의 인터뷰에서 &#8220;치부가마우 금 캠프는 증가하는 관심을 받고 있으며, 퀘벡 최대 은행인 내셔널 뱅크(National Bank)와 캠프를 아이엠골드(IAMGOLD)의 다음 성장 단계로 확인한 아이엠골드의 주관회사를 포함한다&#8221;고 말했다. 마코트는 2025년에도 이 부문에서 긍정적인 M&amp;A 트렌드가 계속될 것으로 예상하고, 퀘벡과 같은 최고의 관할권에 집중할 것이라고 밝혔다.
또한 이 회사는 자사의 온타리오 자산을 온골드 리소스(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/ONGRF#OTCQB">ONGRF</a>)로 분사하였으며, 노던 슈피리어는 62% 지분을 보유하고 있다. 애그니코 이글 마인스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>)는 세계 3위 금 생산업체로 15% 지분을 보유하고 있다. 노던 슈피리어의 주가는 올해 들어 7.25% 하락했다.
<h2>시에라 마드레 골드 앤 실버</h2>
시에라 마드레 골드 앤 실버(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SMDRF#OTC">SMDRF</a>)는 캐나다와 멕시코에서 프로젝트에 주력하는 광물 탐사 회사이다. 이 회사의 대표 프로젝트는 멕시코 톨루카 근처에 위치한 기타라(Guitarra) 은-금 광산이다. 이 프로젝트는 지하에서 운영되기 때문에, 국가에서 논의되고 있는 노천 광산 채굴 금지의 잠재적 영향을 받지 않는다.
이 프로젝트의 총 자원 추정치는 20만 온스의 금과 3,300만 온스 이상의 은이다. 테스트 활동은 이미 250만 달러 이상의 매출을 창출했으며, 전체 상업 채굴 발표가 즉시 예상된다. 주가는 올해 들어 12.50% 상승했다.
<h2>프리드만 인더스트리스</h2>
프리드만 인더스트리스(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FRD#AMEX">FRD</a>)는 국내 철강 제조업체이다. 지난 50년 동안, 이 회사는 북부 및 중부 미국에서 주목할 만한 운영자로 자리 잡았다. 도널드 트럼프의 두 번째 임기가 1월 20일 시작되면서, 국내 철강 부문은 그의 &#8220;미국 우선&#8221; 정책의 초점이 될 것이며, 첫 번째 임기에는 철강 수입에 25% 관세가 포함되었다. 트럼프의 일본제철의 US 스틸 인수에 대한 반대는 조 바이든 대통령과 카멀라 해리스 부통령과의 <a href="https://www.benzinga.com/markets/equities/24/10/41445066/as-trump-kamala-harris-and-biden-unite-against-nippon-steels-15b-us-steel-acquisition-japanese-s" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">의견이 일치한</a> 드문 사례였다.
프리드만 인더스트리스는 11.7%의 높은 헤지 펀드 소유율과 4.8%의 내부자 소유율을 가진 비정상적인 소유 구조를 가지고 있으며, 내부자들은 2024년에만 매입하고 있다. 주가는 올해 들어 2.52% 하락했다.
 
다음 읽기: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42672565/why-trumps-return-to-office-could-drive-gold-demand-in-2025" target="_blank" rel="noreferrer noopener">트럼프의 재임이 2025년 금 수요에 미칠 영향</a>
사진 출처: Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Sierra Madre Gold

뉴스

에 대한 최신 뉴스 Sierra Madre Gold (OTC:SMDRF) 주식

화요일, 12월 31, 2024

뉴스

파트너 / 기고자

벤징가 글로벌